



Supporting Information

Supplementary tables

**This appendix was part of the submitted manuscript and has been peer reviewed.
It is posted as supplied by the authors.**

Appendix to: te Marvelde L, Milne RL, Hornby CJ, et al. Differences in treatment choices for localised prostate cancer diagnosed in private and public health services. *Med J Aust* 2020; doi: 10.5694/mja2.50794.

Table 1. International Statistical Classification of Diseases and Related Health Problems, tenth revision, Australian modification (ICD-10-AM) definitions of biopsy and radical prostatectomy

Procedure	Block	Description	Defined as
3009408	1163	Percutaneous [needle] biopsy of seminal vesicle	Biopsy
3721500		Endoscopic biopsy of prostate	
3721800		Percutaneous [needle] biopsy of prostate	
3721900		Transrectal needle biopsy of prostate	
3007521	1164	Biopsy of seminal vesicle	
3721200		Biopsy of prostate	
3720100	1165	Transurethral needle ablation of the prostate [TUNA]	
3720300		Transurethral resection of the prostate [TURP]	
3720302		Transurethral electrical vaporisation of prostate	
3720303	1166	Cryoablation of prostate	[excluded]
3720304		Microwave thermotherapy of prostate	[excluded]
3720306		Other closed prostatectomy	Radical prostatectomy
3720700		Endoscopic laser ablation of prostate	[excluded]
3720701		Endoscopic laser excision of prostate	[excluded]
3720901		Laparoscopic radical prostatectomy	Radical prostatectomy
3721001		Laparoscopic radical prostatectomy with bladder neck reconstruction	
3721101		Laparoscopic radical prostatectomy with bladder neck reconstruction and pelvic lymphadenectomy	
3720003	1167	Suprapubic prostatectomy	
3720004		Retropubic prostatectomy	
3720005		Other open prostatectomy	
3720900		Radical prostatectomy	
3721000		Radical prostatectomy with bladder neck reconstruction	
3721100		Radical prostatectomy with bladder neck reconstruction and pelvic lymphadenectomy	

Table 2. Treatment during 12 months after diagnosis of 29 325 men diagnosed with prostate cancer in Victoria, 2011–2017, by International Society of Urological Pathology (ISUP) tumour grade and health service type

Health service type	ISUP grade	Number	Treatment in the first year after prostate cancer diagnosis		
			No radical prostatectomy nor curative radiation therapy	Radical prostatectomy with or without associated radiation therapy	Curative external beam radiation therapy only
Public	1	2786	2168 (77.8%)	457 (16.4%)	161 (5.8%)
	2	2006	794 (39.6%)	811 (40.4%)	401 (20.0%)
	3	1128	367 (32.5%)	418 (37.1%)	343 (30.4%)
	4	892	330 (37.0%)	272 (30.5%)	290 (32.5%)
	5	956	520 (54.4%)	162 (16.9%)	274 (28.7%)
	Unknown	398	203 (51.0%)	140 (35.2%)	55 (13.8%)
Private	1	5954	4596 (77.2%)	1261 (21.2%)	97 (1.6%)
	2	5161	1459 (28.3%)	3255 (63.1%)	447 (8.7%)
	3	2312	520 (22.5%)	1402 (60.6%)	390 (16.9%)
	4	1229	359 (29.2%)	622 (50.6%)	248 (20.2%)
	5	1419	645 (45.5%)	462 (32.6%)	312 (22.0%)
	Unknown	533	224 (42.0%)	261 (49.0%)	48 (9.0%)
Unknown	1	1272	993 (78.1%)	229 (18.0%)	50 (3.9%)
	2	907	401 (44.2%)	349 (38.5%)	157 (17.3%)
	3	475	172 (36.2%)	183 (38.5%)	120 (25.3%)
	4	306	128 (41.8%)	90 (29.4%)	88 (28.8%)
	5	401	207 (51.6%)	80 (20.0%)	114 (28.4%)
	Unknown	1190	934 (78.5%)	215 (18.1%)	41 (3.4%)

Table 3. Demographic data for 4551 men diagnosed in a health service for which the health service type (public or private) could not be determined

Age at diagnosis (years)	< 60	791 (17%)
	60-69	1680 (37%)
	70-79	1209 (27%)
	80 or more	871 (19%)
ISUP grade	1	1272 (28%)
	2	907 (20%)
	3	475 (10%)
	4	306 (7%)
	5	401 (9%)
	Unknown	1190 (26%)
VAED-derived Charlson Comorbidity Index (excluding cancer)	None	4321 (95%)
	One or more	230 (5%)
Socio-economic status (quintile)	1 (most disadvantaged)	990 (22%)
	2	1006 (22%)
	3	913 (20%)
	4	857 (19%)
	5 (least disadvantaged)	736 (16%)
	Missing data	49
Area of residence	Major cities	2806 (62%)
	Inner regional	1324 (29%)
	Outer regional/remote	401 (9%)
	Missing data	20

ISUP = International Society of Urological Pathology; VAED = Victorian Admitted Episode Dataset.

Table 4. Sensitivity analyses: treatment during 12 months after diagnosis of men with localised prostate cancer, assuming all with men with unknown health service type for biopsy were diagnosed by either public (A) or private health services (B)

A	Radical prostatectomy (with or without curative radiation therapy)			Curative external beam radiation therapy only		
	Number	Adjusted odds ratio* (95% CI)	<i>P</i>	Number	Adjusted odds ratio* (95% CI)	<i>P</i>
Type of health service of the initial biopsy						
Public + Unknown	3406/12 717 (26.8%)	1	< 0.001	2094/12 717 (16.5%)	1	< 0.001
Private	7263/16 608 (43.7%)	2.31 (2.18–2.45)		1542/16 608 (9.3%)	0.49 (0.46–0.53)	

B	Radical prostatectomy (with or without curative radiation therapy)			Curative external beam radiation therapy only		
	Number	Adjusted odds ratio* (95% CI)	<i>P</i>	Number	Adjusted odds ratio* (95% CI)	<i>P</i>
Type of health service of initial biopsy						
Public	2260/8166 (27.7%)	1	< 0.001	1524/8166 (18.7%)	1	< 0.001
Private + Unknown	8409/21 159 (39.7%)	1.93 (1.81–2.06)		2112/21 159 (10.0%)	0.51 (0.47–0.55)	

* Adjusted for International Society of Urological Pathology tumour grade, age and comorbidity.